Melanoma & Skin Cancer Articles

Long Shares Insight on Pivotal Data in BRAF-Mutant Melanoma
Georgina V. Long, BSc, PhD, MBBS, FRACP, discusses the activity of the combination of dabrafenib and trametinib alone as well as in combination with spartalizumab in patients with advanced BRAF V600E-mutant melanoma.
FDA Approval Sought for Extended Pembrolizumab Dosing Schedule for Select Indications
The FDA has accepted 6 supplemental biologics license applications for review to update the dosing schedule for pembrolizumab (Keytruda) to include an every-6-weeks option at 400 mg over 30-minute infusions.
Cemiplimab Approved in Europe for Cutaneous Squamous Cell Carcinoma
The European Commission approved cemiplimab (Libtayo) for the treatment of adult patients with metastatic or locally advanced cutaneous squamous cell carcinoma who are not candidates for curative surgery or curative radiation.
Adding PD-1 Inhibitor to Dabrafenib/Trametinib May Improve Outcomes in <em>BRAF</em>+ Melanoma
Ryan J. Sullivan, MD, discusses the success with dabrafenib (Tafinlar) plus trametinib (Mekinist) and highlights the potential added benefit of spartalizumab in BRAF-mutant with melanoma.
Atezolizumab/Cobimetinib Combo Misses PFS Endpoint in <em>BRAF</em> V600 Wild-Type Melanoma
The combination of atezolizumab (Tecentriq) and cobimetinib (Cotellic) did not improve progression-free survival compared with pembrolizumab (Keytruda) in patients with previously untreated BRAF V600 wild-type melanoma, missing the primary endpoint of the phase III IMspire170 trial.
Immunotherapy Lessons Learned in Melanoma May Turn Tide in Other Tumors
The use of immunotherapy in cancer was solidified by the ample activity seen in patients with melanoma.
Cemiplimab Nears EU Approval for CSCC
The European Medicines Agency's Committee for Medicinal Products for Human Use issued a positive opinion recommending approval of cemiplimab for the treatment of adult patients with metastatic or locally advanced cutaneous squamous cell carcinoma who are not candidates for curative surgery or curative radiation, according to Regeneron Pharmaceuticals, the manufacturer of the PD-1 inhibitor.
Childhood Cancer Survivors at Increased Risk for Skin Cancers
Childhood cancer survivors who had lived 5 or more years from their primary malignancy are at an increased risk of developing skin cancer compared with the general population.
SITC Guidelines Provide a Fresh Look at Evolving Strategies for Melanoma
New therapeutic approaches for treating patients with earlier-stage melanoma who face a higher risk of recurrence are among the features of recently updated consensus guidelines from the Society for Immunotherapy of Cancer.
The European Medicines Agency’s Committee for Medicinal Products for Human Use has adopted a positive opinion for a new extended dosing schedule for pembrolizumab for all of the PD-1 inhibitor’s monotherapy indications in the European Union.
Publication Bottom Border
Border Publication
x